Alasdair Gunn
About Alasdair Gunn
Alasdair Gunn is a Senior Scientist currently working at Adaptimmune, specializing in cancer immunotherapy and the development of innovative technologies. He has previously held positions at Immunocore and the University of Oxford, and he possesses expertise in integrating laboratory techniques with bioinformatics.
Current Role at Adaptimmune
Alasdair Gunn serves as a Senior Scientist at Adaptimmune, where he has been employed since 2020. In this role, he leads cross-functional project teams aimed at advancing scientific understanding and enhancing the company's research pipelines. His focus on cancer immunotherapy involves the development and implementation of innovative technologies that contribute to the company's objectives.
Previous Experience at Immunocore
Prior to his current position, Alasdair Gunn worked at Immunocore in Didcot. He held the role of Scientist from 2016 to 2018 and then progressed to Senior Scientist from 2019 to 2020. During his time at Immunocore, he contributed to various projects in the field of cancer immunotherapy, leveraging his expertise in novel technologies.
Postdoctoral Research at University of Oxford
Alasdair Gunn completed a Postdoctoral Research Associate position at the University of Oxford from 2015 to 2016. This role allowed him to further develop his skills in cancer immunotherapy and engage in advanced research methodologies. His time at Oxford contributed to his foundation in scientific research and innovation.
Educational Background
Alasdair Gunn has a strong educational background, having studied at the University of Oxford. He earned a DPhil in Systems Biology/Biochemistry from 2011 to 2015 and a Master of Physics (MPhys) from 2007 to 2011. Earlier, he attended Cockermouth School, where he achieved notable GCSE and A-level results, laying the groundwork for his future academic and professional pursuits.
Specialization in Cancer Immunotherapy
Alasdair Gunn specializes in cancer immunotherapy, focusing on the integration of laboratory techniques with bioinformatics. His unique perspective enables him to tackle complex challenges in the field. He is dedicated to advancing the understanding of cancer treatment through innovative research and technology.